farletuzumab ecteribulin, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules
MORAb-202-G000-201
Phase 2 small_molecule active
Quick answer
farletuzumab ecteribulin, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules for Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC). is a Phase 2 program (small_molecule) at Eisai GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eisai GmbH
- Indication
- Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active